BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary Seattle Genetics antibody-based technology and is expected to advance into clinical trials in the first half of 2020.
Under the terms of the agreement, Seattle Genetics has retained rights to the product candidate in the Americas (United States, Canada and Latin American countries), Europe and Japan. BeiGene has been granted exclusive rights to develop and commercialize the product candidate in Asia (except Japan) and the rest of the world. Seattle Genetics will lead global development and BeiGene will fund and operationalize the portion of global clinical trials attributable to its territories. BeiGene will also be responsible for all clinical development and regulatory submissions specific to its territories. Seattle Genetics will receive an upfront payment and is eligible to receive progress-dependent milestones for a total deal value of up to $160 million and tiered royalties on any product sales.
Collaborating with BeiGene on this product candidate has the potential to accelerate its availability both globally and in several key geographic regions, notably China where there is an unmet medical need for anti-cancer therapies, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. BeiGene brings to this collaboration strong clinical and commercial capabilities and a focus on innovative, targeted oncology drugs. We look forward to working together to develop this therapy for patients worldwide.
Seattle Genetics is recognized for its transformative oncology discoveries and we are excited to collaborate on the global development of this new drug candidate. This collaboration ties closely to our mission, to bring meaningful and innovative new medicines to patients around the world, through our commitment to world-class clinical development and commercialization, said Lai Wang, Ph.D., Senior Vice President, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development at BeiGene. The pending start of this new global trial adds a complementary molecule to our broad oncology development program, which now includes more than 60 clinical trials around the world.
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has a late-stage pipeline including enfortumab vedotin for metastatic urothelial cancer, currently being reviewed for approval by the FDA, and tisotumab vedotin in clinical trials for metastatic cervical cancer, which utilize our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,000 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE (nanoparticle albuminbound paclitaxel), REVLIMID (lenalidomide), and VIDAZA (azacitidine) in China under a license from Celgene Corporation.i
Seattle Genetics Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the development and commercialization of the specified product candidate and the possible financial payments from BeiGene to Seattle Genetics. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks associated with developing and commercializing novel drug candidates and that the collaboration agreement may be modified, terminated, or not provide anticipated benefits. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
BeiGene Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding future development and potential commercialization activities of the specified product candidate under the agreement with Seattle Genetics, potential payments payable to Seattle Genetics, the speed and outcome of drug development plans, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
i ABRAXANE, REVLIMID and VIDAZA are registered trademarks of Celgene Corporation.
Read the original here:
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate - Business Wire
- Is ALS Hereditary? Genetics, Inheritance Patterns, and More - Healthline - May 5th, 2024
- Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex traits ... - Nature.com - May 5th, 2024
- Genetic association of inflammatory marker GlycA with lung function and respiratory diseases - Nature.com - May 5th, 2024
- Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy - Nature.com - May 5th, 2024
- Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute ... - Nature.com - May 5th, 2024
- Pitfalls in the genetic testing of the OPN1LW-OPN1MW gene cluster in human subjects | npj Genomic Medicine - Nature.com - May 5th, 2024
- Reply to: Pitfalls in the genetic testing of the OPN1LW-OPN1MW gene cluster in human subjects | npj Genomic Medicine - Nature.com - May 5th, 2024
- Lifespan is influenced more by lifestyle than genetics - Earth.com - May 5th, 2024
- Scientists discover over 100 new genomic regions linked to blood pressure - National Institutes of Health (NIH) (.gov) - May 5th, 2024
- Genetics studies have a diversity problem that researchers struggle to fix - The Lund Report - May 5th, 2024
- Researchers discover the genetic cause of the most common brain malformation - EL PAS USA - May 5th, 2024
- Genetic link between adolescent drinking and adult anxiety may offer therapy target | UIC today - UIC Today - May 5th, 2024
- Phylogenomics and genetic analysis of solvent-producing Clostridium species | Scientific Data - Nature.com - May 5th, 2024
- New genes are involved in the adaptation of acorn barnacles to sessile life - Nature.com - May 5th, 2024
- Rachel Khong explores genetics, race and the idea of being American in new novel - Wyoming Public Media - May 5th, 2024
- Genetic testing led to early cancer detection for father, daughter - Roswell Park Comprehensive Cancer Center - May 5th, 2024
- EYE ON HEALTH: High risk and genetic testing being offered at local hospital - Local 3 News - May 5th, 2024
- Fatty Liver: Is It Hereditary? - Healthline - May 5th, 2024
- Southern Seven Health Department to expand genetic cancer testing - KFVS - May 5th, 2024
- Genetic associations of key genes in breast cancer pathogenesis - News-Medical.Net - May 5th, 2024
- Mating Study Unlocks the Genetic Code of Attraction - Neuroscience News - March 18th, 2024
- Mindfulness in your DNA? Capacity to be present is partly a function of genetics, study finds - PsyPost - March 18th, 2024
- Genetic testing scam targets Medicare recipients, including those in Spokane - KXLY Spokane - March 18th, 2024
- Some people are genetically predisposed to gain weight. These 5 tips can help - CNN - March 18th, 2024
- SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear ... - PR Newswire - March 18th, 2024
- Tissue samples show the deep genetic and cellular impacts of smoking - Medical Xpress - March 18th, 2024
- The regulatory landscape of chromatin accessibility - Nature.com - March 18th, 2024
- Genome assemblies of 11 bamboo species highlight diversification induced by dynamic subgenome dominance - Nature.com - March 18th, 2024
- Research reveals the genetic code behind non-identical twins - Medical Xpress - March 18th, 2024
- How genetic therapies transformed the lives of sickle cell patients - KPVI News 6 - March 18th, 2024
- The Next Wave of Privacy Litigation: The Illinois Genetic Information Privacy Act - Perkins Coie - March 18th, 2024
- State initiates study on genetic cancers, Lynch Syndrome - The Times of India - March 18th, 2024
- How genetic therapies transformed the lives of sickle cell patients - Citizentribune - March 18th, 2024
- Dr Plichta on Areas of Interest for Genetic Testing Research in Breast Cancer - OncLive - March 18th, 2024
- The Genetic History of the Jews Mosaic - Mosaic - March 18th, 2024
- New insights into genetic mechanisms could improve treatment of liver fibrosis - Medical Xpress - March 18th, 2024
- 5 Questions To Ask About The Ethics Of Genetic Data - Forbes - March 18th, 2024
- Couple raising money to fix sons club feet caused by rare genetic condition - 21 Alive News - February 18th, 2024
- What can bulls tell us about men? Genetic discovery could translate to human fertility research - Medical Xpress - February 18th, 2024
- Legislation seeks to bar life insurance companies from purchasing recreational genetic testing data - Delaware First Media - February 18th, 2024
- Family-based study identifies potential new genetic factors linked to Alzheimer's risk in people with African ancestry - National Institute on Aging - February 18th, 2024
- Genetic determinants of micronucleus formation in vivo - Nature.com - February 18th, 2024
- Near-gapless and haplotype-resolved apple genomes provide insights into the genetic basis of rootstock-induced ... - Nature.com - February 18th, 2024
- Accurate and sensitive mutational signature analysis with MuSiCal - Nature.com - February 18th, 2024
- CRISPR, the Genetic Revolution of the 21st Century | OpenMind - BBVA OpenMind - February 18th, 2024
- Genetic control of thermomorphogenesis in tomato inflorescences - Nature.com - February 18th, 2024
- Natural selection and genetic diversity maintenance in a parasitic wasp during continuous biological control application - Nature.com - February 18th, 2024
- Understanding how natural genetic variation contributes to adaptive responses to low oxygen - News-Medical.Net - February 18th, 2024
- Division of Epidemiology and Genetics - Epidemiology and Genetics - University of Southern California - February 18th, 2024
- Genetic study clarifies the link between birth weight and adult morbidity - Medical Xpress - February 18th, 2024
- AI and genetics underpin project to speed up CVD diagnosis and personalise treatment - Hospital Healthcare - February 18th, 2024
- Study Reveals Complex Interaction Between Genetics and Environment in Brain Functioning - Medriva - February 18th, 2024
- Unraveling the Impact of Genetics and Socioeconomic Status on Behavioral and Psychiatric Traits - Medriva - February 18th, 2024
- Genetic Investigation Reveals CETP Gene Variants Linked to Cardiovascular Resilience in Genome-Wide Association ... - Physician's Weekly - December 30th, 2023
- Raha Kapoor's blue eyes remind fans of her great-grandfather, Raj Kapoor; here's what genetics says - IndiaTimes - December 30th, 2023
- Genetic clue to pericarditis inflammation points to promising new treatments - News-Medical.Net - December 30th, 2023
- Certain genetic predispositions may increase risk of atrial fibrillation among those with high alcohol consumption - 2 Minute Medicine - December 30th, 2023
- Understanding the genetic basis of hereditary diffuse gastric cancer - News-Medical.Net - December 30th, 2023
- Genetic engineering was meant to save chestnut trees. Then there was a mistake. - The Washington Post - December 30th, 2023
- Unraveling the mystery of hereditary diffuse gastric cancer - EurekAlert - December 30th, 2023
- What is Genetics? | AMNH - American Museum of Natural History - December 22nd, 2023
- Who killed Shelley Connolly? Genetic genealogy leads authorities to a suspect and a conviction - Alaska's News Source - December 22nd, 2023
- C.S. Lewis, Atheism, and the Genetic Fallacy - Word on Fire - December 22nd, 2023
- FDA approves first genetic test to assess opioid addiction risk using DNA sample - Fox News - December 22nd, 2023
- Genetic blueprint of wild grapes could help breed better grapes - University of California, Davis - December 22nd, 2023
- Unlocking the genetic secrets of grape seedlessness - Phys.org - December 22nd, 2023
- Unlocking the genetic secrets of drought resilience in Persian walnuts - Phys.org - December 22nd, 2023
- FDA approves genetic test to assess patients risk of developing an opioid addiction - KXAN.com - December 22nd, 2023
- How researchers are CReATiNG synthetic chromosomes faster and cheaper - EurekAlert - December 22nd, 2023
- The promise of genetic therapies in sickle cell disease - The Lancet - December 22nd, 2023
- Assessment of genetic diversity, population structure and wolf-dog hybridisation in the Eastern Romanian Carpathian ... - Nature.com - December 22nd, 2023
- Genetics and Heart Disease: What you need to know - IndiaTimes - December 22nd, 2023
- How to become a geneticist - University of Sydney - December 22nd, 2023
- Study sheds light on the ancestry and genetics of Coast Salish woolly dogs | News | Vancouver Island University ... - Vancouver Island University News - December 22nd, 2023
- Human genetics | Description, Chromosomes, & Inheritance - December 13th, 2023
- BASIC GENETICS INFORMATION - Understanding Genetics - NCBI Bookshelf - December 13th, 2023
- Introduction to Genetics - Open Textbook Library - December 13th, 2023
- Clues to preventing Alzheimer's come from patient who, despite genetics, evaded disease Washington University ... - Washington University School of... - December 13th, 2023
- Environmental stress rather than genetics influenced height differences in early Neolithic people: Study - Phys.org - December 13th, 2023
- What is trisomy 18? Why the fatal genetic disorder is in the news and what it's like to get the diagnosis. - Yahoo Life - December 13th, 2023